VYGR -18%/AH on CMC issues with HD program: https://finance.yahoo.com/news/voyager-therapeutics-provides-regulatory-vy-200100042.html Voyager Therapeutics…today announced that it has received feedback from the U.S. Food and Drug Administration (FDA) on the Investigational New Drug (IND) submission for VY-HTT01 for the treatment of Huntington’s disease. Voyager submitted the IND for VY-HTT01 in September 2020 and has been notified that the IND was placed on clinical hold pending the resolution of certain chemistry, manufacturing and controls (CMC) matters.